United Capital Management of KS’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.1M | Buy |
12,627
+110
| +0.9% | +$112K | 1.98% | 22 |
|
|
2026
Q1 | $11.5M | Hold |
12,517
| – | – | 1.74% | 22 |
|
|
2025
Q4 | $13.5M | Buy |
12,517
+55
| +0.4% | +$52.6K | 1.88% | 21 |
|
|
2025
Q3 | $9.51M | Buy |
12,462
+149
| +1% | +$111K | 1.29% | 27 |
|
|
2025
Q2 | $9.6M | Buy |
12,313
+2
| +0% | +$1.55K | 1.5% | 23 |
|
|
2025
Q1 | $10.2M | Sell |
12,311
-6
| -0% | -$4.99K | 2.1% | 12 |
|
|
2024
Q4 | $9.51M | Buy |
12,317
+84
| +0.7% | +$69.6K | 1.73% | 16 |
|
|
2024
Q3 | $10.8M | Sell |
12,233
-6
| -0% | -$5.39K | 2.36% | 13 |
|
|
2024
Q2 | $11.1M | Sell |
12,239
-33
| -0.3% | -$26.4K | 2.44% | 13 |
|
|
2024
Q1 | $9.55M | Sell |
12,272
-100
| -0.8% | -$71.2K | 2.19% | 15 |
|
|
2023
Q4 | $7.21M | Sell |
12,372
-368
| -3% | -$215K | 2.18% | 13 |
|
|
2023
Q3 | $6.84M | Buy |
12,740
+7,846
| +160% | +$4.04M | 2.33% | 13 |
|
|
2023
Q2 | $2.3M | Sell |
4,894
-290
| -6% | -$122K | 0.74% | 47 |
|
|
2023
Q1 | $1.78M | Sell |
5,184
-395
| -7% | -$133K | 0.66% | 50 |
|
|
2022
Q4 | $2.04M | Sell |
5,579
-290
| -5% | -$103K | 0.84% | 43 |
|
|
2022
Q3 | $1.9M | Sell |
5,869
-125
| -2% | -$39.6K | 0.89% | 44 |
|
|
2022
Q2 | $1.94M | Sell |
5,994
-627
| -9% | -$188K | 0.91% | 47 |
|
|
2022
Q1 | $1.9M | Sell |
6,621
-138
| -2% | -$35.5K | 0.74% | 52 |
|
|
2021
Q4 | $1.87M | Buy |
6,759
+107
| +2% | +$27.1K | 0.7% | 52 |
|
|
2021
Q3 | $1.54M | Sell |
6,652
-288
| -4% | -$71.1K | 0.63% | 53 |
|
|
2021
Q2 | $1.59M | Buy |
6,940
+236
| +4% | +$47.4K | 0.65% | 53 |
|
|
2021
Q1 | $1.25M | Sell |
6,704
-105
| -2% | -$20.5K | 0.58% | 54 |
|
|
2020
Q4 | $1.15M | Buy |
6,809
+204
| +3% | +$30.5K | 0.53% | 53 |
|
|
2020
Q3 | $977K | Buy |
6,605
+707
| +12% | +$109K | 0.51% | 54 |
|
|
2020
Q2 | $968K | Buy |
5,898
+345
| +6% | +$53K | 0.56% | 55 |
|
|
2020
Q1 | $770K | Buy |
5,553
+255
| +5% | +$35K | 0.65% | 50 |
|
|
2019
Q4 | $696K | Buy |
5,298
+544
| +11% | +$63.1K | 0.44% | 67 |
|
|
2019
Q3 | $513K | Buy |
4,754
+231
| +5% | +$25.7K | 0.37% | 75 |
|
|
2019
Q2 | $510K | Buy |
4,523
+152
| +3% | +$17.9K | 0.39% | 71 |
|
|
2019
Q1 | $516K | Buy |
4,371
+446
| +11% | +$54.2K | 0.4% | 69 |
|
|
2018
Q4 | $454K | Buy |
3,925
+49
| +1% | +$5.47K | 0.42% | 71 |
|
|
2018
Q3 | $410K | Buy |
+3,876
| New | +$388K | 0.33% | 77 |
|
Other funds holding LLY
United Capital Management of KS's LLY Position: Q2 2026 in Review
United Capital Management of KS increased its Eli Lilly (LLY) stake by 0.88% in Q2 2026, buying an estimated $112K and bringing the position to 12,627 shares worth $15.1M. The position accounts for 1.98% of the portfolio, ranked #22.
United Capital Management of KS first reported a position in LLY in Q3 2018 and has held it in 32 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- United Capital Management of KS held 12,627 shares of Eli Lilly worth $15.1M as of Q2 2026.
- United Capital Management of KS bought 110 Eli Lilly shares in Q2 2026, an estimated $112K.
- Eli Lilly made up 1.98% of United Capital Management of KS's portfolio in Q2 2026, its #22 holding.
- United Capital Management of KS first reported a position in Eli Lilly in Q3 2018 and has held it in 32 quarters since.
- 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on United Capital Management of KS's 13F filing for Q2 2026, filed 5 Aug 2026.